Results for glycemic translation from English to Maltese

data indicated that insulin glulisine administered 2 minutes before the meal gives similar postprandial glycemic control compared to
id- data indikat li meta l- insulina glulisine tingħata 2 minuti qabel l- ikla din tagħti l- istess kontroll tal- glukosju wara li jittieħed l- ikel, daqs l- insulina regolari umana meta din ingħatat 30 minuta qabel l- ikla.

therefore, 1,5-ag assays should not be used for assessment of glycemic control in patients on canagliflozin.
għalhekk, assaġġi ta’ 1,5-ag m’għandhomx jintużaw għal stima ta’ kontroll gliċemiku f’pazjenti fuq canagliflozin.

data indicated that insulin glulisine administered 2 minutes before the meal gives similar postprandial glycemic control compared to regular human insulin given 30 minutes before the meal.
id-data indikat li meta l-insulina glulisine tingħata 2 minuti qabel l-ikla din tagħti l-istess kontroll tal-glukosju wara li jittieħed l-ikel, daqs l-insulina regolari umana meta din ingħatat 30 minuta qabel l-ikla.

insulin glulisine administered 15 minutes after starting the meal gives similar glycemic control as regular human insulin given 2 minutes before the meal (see figure 1).
l-insulina glulisine mogħtija 15-il minuta wara li tibda tittiekel l-ikla, tipprovdi l-istess kontroll tal-livelli tal-glukosju fid- demm daqs l-insulina regolari umana mogħtija 2 minuti qabel l-ikla (ara figura 1).

25 mg) as add-on therapy in patients with in sufficient glycemic control on metformin monotherapy was evaluated in a double blind placebo-controlled study of 16 weeks duration.
10 mg u 25 mg) bħala terapija addizzjonali f’pazjenti b’kontroll gliċemiku suffiċjenti fuq monoterapija b’metformin ġew evalwati fi studju double blind ikkontrollat bi plaċebo li dam 16-il ġimgħa.

type 1 diabetes mellitus-adults in a 26-week phase iii clinical study comparing insulin glulisine with insulin lispro both injected subcutaneously shortly (0-15 minutes) before a meal in patients with type 1 diabetes mellitus using insulin glargine as basal insulin, insulin glulisine was comparable to insulin lispro for glycemic control as reflected by changes in glycated haemoglobin (expressed as hba1c equivalent) from baseline to endpoint.
dijabete mellitus tat- tip i - adulti fi studju komparattiv, fil- fażi iii, tul ta ’ 26 ġimgħa, fejn l- insulina glulisine u l- insulina lispro ingħataw taħt il- ġilda ftit ħin (0 sa 15- il minuta) qabel ikla, f’ pazjenti bid- dijabete tat- tip i, fil- waqt li l- insulina glargine intużat bħala insulina bażika, l- insulina glulisine kienet komparabbli ma ’ l- insulina lispro fil- kontroll taz- zokkor fid- demm, kif rifless fil- bidliet ta ’ l- emoglobina glycated (espressa bħala l- ekwivalenti ta ’ hba1c), mil- linja bażi sat- tmiem.